We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.82B
AUM Growth
+$1.31B
Cap. Flow
+$158M
Cap. Flow %
2.03%
Top 10 Hldgs %
19.27%
Holding
869
New
65
Increased
350
Reduced
240
Closed
81

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$43.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$30.4M
3
GILD icon
Gilead Sciences
GILD
+$28.3M
4
BIIB icon
Biogen
BIIB
+$26.7M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$25.2M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$75.2M
2
LOXO
Loxo Oncology, Inc
LOXO
+$28.1M
3
DHR icon
Danaher
DHR
+$27.9M
4
A icon
Agilent Technologies
A
+$26.4M
5
MKC icon
McCormick & Company Non-Voting
MKC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 33.36%
2 Technology 15.96%
3 Financials 11.25%
4 Consumer Discretionary 8.98%
5 Communication Services 7.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVDA icon
76
NVIDIA
NVDA
$5.01T
$22.8M 0.29%
5,077,800
-336,520
-6% -$1.31M
BHVN
77
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$22.8M 0.29%
442,799
-105,000
-19% -$4.54M
ATVI
78
DELISTED
Activision Blizzard
ATVI
$22.6M 0.29%
495,518
+256,600
+107% +$11.6M
ISRG icon
79
Intuitive Surgical
ISRG
$121B
$22.2M 0.28%
116,922
-20,916
-15% -$3.72M
SLB icon
80
SLB Ltd
SLB
$77.8B
$22M 0.28%
504,359
+111,901
+29% +$4.84M
ELV icon
81
Elevance Health
ELV
$81.9B
$21.7M 0.28%
75,749
+4,274
+6% +$1.24M
TECH icon
82
Bio-Techne
TECH
$11.2B
$21.5M 0.28%
433,668
+95,712
+28% +$4.31M
RETA
83
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$21.3M 0.27%
249,200
+50,000
+25% +$4.15M
MELI icon
84
Mercado Libre
MELI
$91.3B
$21.3M 0.27%
41,926
+20,973
+100% +$8.36M
SGEN
85
DELISTED
Seagen Inc. Common Stock
SGEN
$21M 0.27%
286,869
+145,495
+103% +$10.4M
CMCSA icon
86
Comcast
CMCSA
$79.1B
$20.4M 0.26%
509,734
-398,670
-44% -$15M
XYL icon
87
Xylem
XYL
$28.5B
$20.3M 0.26%
257,268
+32,884
+15% +$2.4M
TMO icon
88
Thermo Fisher Scientific
TMO
$211B
$20M 0.26%
73,071
-14,335
-16% -$3.57M
PTC icon
89
PTC
PTC
$13.7B
$19.8M 0.25%
214,696
-19,846
-8% -$1.76M
CLVS
90
DELISTED
Clovis Oncology, Inc.
CLVS
$19.4M 0.25%
781,623
+488,523
+167% +$12.2M
INTU icon
91
Intuit
INTU
$81.1B
$19.4M 0.25%
74,164
-13,842
-16% -$3.2M
NAVG
92
DELISTED
Navigators Group Inc
NAVG
$19.1M 0.24%
273,901
+111,401
+69% +$7.77M
DD icon
93
DuPont de Nemours
DD
$18.6B
$19M 0.24%
132,586
+14,748
+13% +$2.05M
BKNG icon
94
Booking.com
BKNG
$138B
$18.9M 0.24%
269,925
+133,100
+97% +$9.5M
PANW icon
95
Palo Alto Networks
PANW
$264B
$18.4M 0.24%
455,076
-47,382
-9% -$1.76M
ADI icon
96
Analog Devices
ADI
$181B
$18.4M 0.24%
174,894
+44,413
+34% +$4.46M
MET icon
97
MetLife
MET
$61B
$18M 0.23%
392,146
-19,783
-5% -$875K
IMMU
98
DELISTED
Immunomedics Inc
IMMU
$18M 0.23%
935,887
+39,511
+4% +$637K
CBRE icon
99
CBRE Group
CBRE
$40.8B
$17.6M 0.23%
332,710
+56,339
+20% +$2.65M
SBUX icon
100
Starbucks
SBUX
$118B
$17.4M 0.22%
234,462
+40,911
+21% +$2.81M
2 3
4
5 6

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q1 2019 Portfolio in Review

As of Q1 2019, Candriam SCA held 869 positions worth $7.82B, up 20% from $6.51B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Candriam SCA's Q1 2019 filing shows 65 new, 350 increased, 240 reduced and 81 closed positions. Its largest new stake was Baozun: 640,000 shares worth $26.6M. The largest sale was Celgene Corp, an estimated $75.2M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 35% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q1 2019 buy was Baozun: 640,000 shares worth $26.6M.
  • Candriam SCA added most to Merck in Q1 2019, an estimated $43.7M increase.
  • Candriam SCA's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $75.2M.
  • Candriam SCA fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $28.1M.
  • Candriam SCA's ten largest holdings make up 19% of its $7.82B portfolio in Q1 2019.
  • Candriam SCA opened 65 new positions and closed 81 in Q1 2019.
  • Candriam SCA's portfolio value rose 20% quarter-over-quarter to $7.82B.

Based on Candriam SCA's 13F filing for Q1 2019, filed 2 May 2019.